ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totalling 25,600 shares, a decrease of 34.4% from the November 30th total of 39,000 shares. Approximately 1.1% of the shares of the stock are short sold. Based on an average daily volume of 1,240,000 shares, the short-interest ratio is currently 0.0 days.

ZyVersa Therapeutics Trading Down 6.5 %

Shares of NASDAQ:ZVSA opened at $1.15 on Friday. ZyVersa Therapeutics has a 52 week low of $0.98 and a 52 week high of $25.00. The company’s fifty day moving average is $1.38 and its 200 day moving average is $2.59.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.